Blood coagulation and inflammation in acute lung injury

Journal of Organ Dysfunction

Volumn 5, Issue 2, 2009, Pages 101-109

  Ferrer, Ricard ^a   Adda, Mlanie ^a   Navas, Ana ^a   Pasini, Maddalena ^b   Artigas, Antoni ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Dipartimento di Scienze Chirurgiche Anestesiologiche e Radiologiche   (Italy)

Author keywords

Acute respiratory distress syndrome; Drotrecogin alpha activated; Fibrin; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; DROTRECOGIN; FIBRIN; FIBRIN DEGRADATION PRODUCT; INTERLEUKIN 1; INTERLEUKIN 6; NITRIC OXIDE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULATION; ARTIFICIAL VENTILATION; BLOOD CLOTTING; CELL AGGREGATION; FIBROBLAST; HEMOSTASIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LUNG EDEMA; LUNG FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 70849101242     PISSN: 17471060     EISSN: 17471079     Source Type: Journal    
DOI: 10.1080/17471060701388645     Document Type: Review

References (55)

1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;/149:/818-24. (Pubitemid 24082248)
2. Hudson L, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995;/151:/293-301.
3. Ferrer R, Bauer T, Torres T. Nosocomial pneumonia during acute respiratory distress syndrome. Clin Intensive Care 2001;/12:/43-51.
4. Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. Intensive Care Med 2006;/32:/ 24-33.
5. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301-1308
6. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982;/3:/35-56.
7. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;/342:/1334-49.
8. Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976;/61:/585-9.
9. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia*a review. Crit Care Med 2006;/34:/ 871-877
10. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991;/261:/L240-8.
11. Gray AJ, Bishop JE, Reeves JT, Mecham RP, Laurent GJ. Partially degraded fibrin(ogen) stimulates fibroblast proliferation in vitro. Am J Respir Cell Mol Biol 1995;/12:/684-90.
12. Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O, Masugi Y. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 1987;/126:/171-82.
13. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000;/22:/401-4.
14. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;/344:/699-709.
15. Russell JA. Management of sepsis. N Engl J Med 2006;/355:/ 1699-1713
16. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;/101:/816-23.
17. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;/345:/408-16. (Pubitemid 32747604)
18. Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 2006;/10:/R92.
19. Hack CE. Fibrinolysis in disseminated intravascular coagulation. Semin Thromb Hemost 2001;/27:/633-8.
20. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;/407:/258-64.
21. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokinemediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003;/14:/523-35.
22. Pugin J, Verghese G, Widmer MC, Matthay MA. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 1999;/27:/304-12.
23. Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F, Park DR, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;/164:/1896-903.
24. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horiz 1994;/2:/566-74.
25. Fuchs-Buder T, de Moerloose P, Ricou B, Reber G, Vifian C, Nicod L, et al. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;/153:/163-7.
26. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989;/ 84:/695-705. (Pubitemid 19197006)
27. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;/161:/ 454-462
28. Van Till JW, Levi M, Bresser P, Schultz MJ, Gouma DJ, Boermeester MA. Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis. J Infect Dis 2006;/194:/1331-9.
29. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;/285:/L514-21.
30. Matthay MA, Ware LB. Plasma protein C levels in patients with acute lung injury: prognostic significance. Crit Care Med 2004;32(5 Suppl):S229-32.
31. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990;/322:/890-7.
32. Zapol WM, Jones R. Vascular components of ARDS. Clinical pulmonary hemodynamics and morphology. Am Rev Respir Dis 1987;/136:/471-4.
33. Greene R. Pulmonary vascular obstruction in the adult respiratory distress syndrome. J Thorac Imaging 1986;/1:/31-8.
34. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 2002;/346:/1281-6.
35. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003;31(4 Suppl):S213-20.
36. Rowland FN, Donovan MJ, Picciano PT, Wilner GD, Kreutzer DL. Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction. Am J Pathol 1984;/117:/418-28.
37. Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax 1998;/53:/ 815-817 (Pubitemid 28459534)
38. Seeger W, Grube C, Gunther A. Proteolytic cleavage of fibrinogen: amplification of its surfactant inhibitory capacity. Am J Respir Cell Mol Biol 1993;/9:/239-47.
39. Stevens T, Garcia JG, Shasby DM, Bhattacharya J, Malik AB. Mechanisms regulating endothelial cell barrier function. Am J Physiol Lung Cell Mol Physiol 2000;/279:/L419-22.
40. Trepat X, Grabulosa M, Buscemi L, Rico F, Farre R, Navajas D. Thrombin and histamine induce stiffening of alveolar epithelial cells. J Appl Physiol 2005;/98:/1567-74.
41. Gross TJ, Simon RH, Kelly CJ, Sitrin RG. Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase. Am J Physiol 1991;/260:/L286-95.
42. Idell S, Kumar A, Zwieb C, Holiday D, Koenig KB, Johnson AR. Effects of TGF-beta and TNF-alpha on procoagulant and fibrinolytic pathways of human tracheal epithelial cells. Am J Physiol 1994;/267:/L693-703.
43. Moalli R, Doyle JM, Tahhan HR, Hasan FM, Braman SS, Saldeen T. Fibrinolysis in critically ill patients. Am Rev Respir Dis 1989;/140:/287-93.
44. Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med 2003;31(4 Suppl):S329- 36.
45. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;/290:/238-47.
46. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;/ 286:/1869-78.
47. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFIdependent. Blood 1996;/88:/2093-100.
48. Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, et al. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005;/9(Suppl 4):/S38-45.
49. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004;/104:/ 3878-3885
50. Laterre PF, Garber G, Levy H,Wunderink R, Kinasewitz GT, Sollet JP, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005;/33:/952-61.
51. Van der Poll PT, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005;/171:/1125-8.
52. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, et al. Coagulation blockade prevents sepsisinduced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001;/164:/1988-96.
53. Hardaway RM, Williams CH, Marvasti M, Farias M, Tseng A, Pinon I, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990;/18:/1413-8.
54. Greene R, Lind S, Jantsch H, Wilson R, Lynch K, Jones R, et al. Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapy. AJR Am J Roentgenol 1987;/148:/501-8.
55. Gunther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003;/168:/1358-65.